Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure

Sep 28 2016

• By Joseph Haas

Liver

Related Content

The NASH Pipeline: Replete With Targets And New Compounds

Aug 29 2016

NASH Drugs Soon May Have A Registrational Pathway, Finally

Mar 30 2015

Conatus' Liver Focus Goes Well Beyond NASH

Nov 30 2015

Searching For Surrogate Endpoints Requires Teamwork

Sep 30 2013

'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Jun 06 2016

Related Companies

Galectin Therapeutics Inc.

Gilead Sciences, Inc.

Conatus Pharmaceuticals Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Additional Topics

Drug Approval Standards Clinical Trials Research & Development Liver & Hepatic Diagnostics BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window